122
Participants
Start Date
April 30, 2007
Primary Completion Date
August 31, 2008
Study Completion Date
January 31, 2010
LX201
"LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
Placebo
The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
New York Eye and Ear Infirmary, New York
Mount Sinai School of Medicine, New York
Ophthalmic Consultants of Long Island, Rockville Centre
Cornea Consultants of Albany, Slingerlands
The Eye Center at Union Memorial Hospital, Baltimore
Wilmer Eye Institute, Cornea Service, Baltimore
Virginia Eye Consultants, Norfolk
Klinik fuer Ophthalmologie Campus Kiel, Kiel
Duke University Eye Center, Durham
Emory Eye Center, Atlanta
Bascom Palmer Eye Institute, Miami
University Hospitals Case Medical Center, Cleveland
Cornea Bank, Universitätsklinikum Essen, Essen
Price Vision Group, Indianapolis
W.K. Kellogg Eye Center - University of Michigan, Ann Arbor
MN Eye Consultants, P.A., Bloomington
University of Illinois at Chicago, Chicago
Ophthalmology Associates, St Louis
Tauber Eye Center, Kansas City
Cornea Associates of Texas, Dallas
Ludwig Maximilians Universität, München
Augenklinik der Technischen Universität München, München
Cornea Consultants of Arizona, Phoenix
USC Doheny Eye Institute, Los Angeles
Augenklinik, Universitat Erlangen-Nurnberg, Erlangen
Loma Linda University Health Care, Loma Linda
Augenklinik Wuerzburg, Würzburg
Eye Associates NW, Seattle
New England Eye Center, Boston
UMDNJ - New Jersey Medical School Institute of Ophthalmology and Visual Science, Newark
Lead Sponsor
Lux Biosciences, Inc.
INDUSTRY